会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent
    • 组蛋白脱乙酰酶(Hdac)抑制剂(Pxd101)用于单独治疗癌症或与化疗药物组合
    • US20080274120A1
    • 2008-11-06
    • US12093069
    • 2006-11-10
    • Henri LichensteinNicholas EdwardsJames RitchieKamille Dumong PetersenJane Plumb
    • Henri LichensteinNicholas EdwardsJames RitchieKamille Dumong PetersenJane Plumb
    • A61K31/395A61K31/195A61P35/02C12N5/00A61P35/00
    • A61K31/475A61K31/10A61K31/185A61K31/196A61K31/573A61K31/65A61K31/69A61K39/3955A61K45/06A61K2300/00
    • The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, Avastin®, an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
    • 本发明一般涉及治疗癌症的方法。 在一个方面,本发明涉及一种治疗血液癌症(例如多发性骨髓瘤,白血病,淋巴瘤)的方法,包括向有需要的患者施用治疗有效量的组蛋白脱乙酰酶抑制剂,例如组蛋白脱乙酰酶 (HDAC)抑制剂,例如PXD-101。 在另一方面,本发明涉及一种治疗癌症的方法(例如,实体肿瘤癌症,例如直肠癌,结肠癌,卵巢癌;血液癌症,例如多发性骨髓瘤,白血病,淋巴瘤),其包括向患者施用 需要第一量的组蛋白脱乙酰酶(HDAC)抑制剂,例如本文所述的组蛋白脱乙酰酶抑制剂,例如PXD-101,和第二量的其它化学治疗剂,例如其它化学治疗剂 选自:针对VEGF的抗体,Avastin,针对CD20的抗体,利妥昔单抗,硼替佐米,沙利度胺,地塞米松,长春新碱,多柔比星和美法仑,其中第一和第二量一起包含治疗有效量。